Thus, our study has exhibited the potential value of LARP1 in predicting patient survival in subgroups with normal AFP levels or in the early-stage HCC group, which would have been difficult using currently clinically available surrogate biomarkers. The gene discussed is AFP; the disease is hepatocellular carcinoma.